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Abstract
It has been found that the majority of disease-associated genetic variants 
identified by genome-wide association studies are located outside of protein-
coding regions, where they seem to affect regions that control transcription 
(promoters, enhancers) and non-coding RNAs that also can influence gene 
expression. In this review, we focus on two classes of non-coding RNAs that 
are currently a major focus of interest: micro-RNAs and long non-coding RNAs. 
We describe their biogenesis, suggested mechanism of action, and discuss 
how these non-coding RNAs might be affected by disease-associated genetic 
alterations. The discovery of these alterations has already contributed to a 
better understanding of the etiopathology of human diseases and yielded insight 
into the function of these non-coding RNAs. We also provide an overview of 
available databases, bioinformatics tools, and high-throughput techniques that 
can be used to study the mechanism of action of individual non-coding RNAs.
Introduction
Genome-wide association studies 
(GWAS) have discovered thousands 
of single-nucleotide polymorphisms 
(SNPs) that are associated with 
multifactorial diseases and 
quantitative traits. At the time of 
writing of this review (October 2013), 
the GWAS catalog [1] described 
11,680 SNPs associated with diverse 
phenotypes and quantitative traits. 
Despite the wealth of information that 
GWAS provide, it can be difficult to 
interpret the results because of the 
limited resolution of the genome-wide 
chips used in the initial genotyping 
screen. Moreover, even state-of-the-
art technology and approaches, such 
as using specialized high-resolution 
genotyping platforms (for example, the 
Immunochip [2] and Metabochip [3]), 
performing genotype imputation [4], or 
eQTL analysis [5], is often not enough 
to pinpoint the functional SNP and/
or causative gene. What is emerging 
from these GWAS, however, is that 
>90% of disease-associated SNPs 
are located in non-coding regions of 
the genome for example in promoter 
regions, enhancers, or even in non-
coding RNA genes [1,6]. This indicates 
that these SNPs might be regulatory. 
The results from the Encyclopedia of 
the DNA Elements (ENCODE) project 
suggest that 80% of the human 
genome is involved in at least one 
biochemical RNA- and/or chromatin-
associated event [7]. While fewer than 
10% of the GWAS SNPs affect coding 
sequences, most non-coding variants 
are concentrated in DNA stretches 
marked by deoxyribonucleaseI 
(DNase I) hypersensitive sites, where 
they seem to perturb transcription 
factor binding sites or alter allelic 
chromatin states [8]. A small 
percentage seems to disrupt or 
create micro-RNA (miRNA) binding 
sites in the 3’ untranslated region 
(3’-UTR) of genes. All these events 
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will affect the expression level of the 
genes regulated by these functional 
elements and can thereby contribute 
to deregulation of pathways that 
control healthy cell function.
 The recent discovery of 
approximately 13,500 long non-
coding RNAs (lncRNAs) has changed 
the view on the human genome 
(Figure 1). It has been estimated that 
approximately 7% of SNPs associated 
with autoimmune diseases seem 
to annotate to long intergenic non-
coding RNAs (lincRNAs), a subclass 
of lncRNAs [6], and some GWAS 
SNPs have been demonstrated to 
have eQTL-effects on these lincRNAs 
[9]. It is thought that the majority of 
lncRNAs are somehow involved in 
regulating the expression of protein-
coding genes and, therefore, SNPs 
associated with these ncRNAs may 
indirectly influence the expression 
of proteins involved in disease. In 
this review we will describe how two 
classes of regulatory ncRNAs, the 
miRNAs and the lncRNAs, regulate 
gene expression. We will also describe 
how SNPs and other types of genetic 
variation that affect these ncRNAs can 
contribute to disease phenotypes.
miRNAs
miRNAs are short regulatory RNAs 
(approximately 19-24 nucleotides 
long) involved in post-transcriptional 
gene regulation. The first miRNA, lin-
4, was identified in 1993 in a screen 
for genes required for post-embryonic 
development in C. elegans [10], but it 
took another seven years to discover 
the second one (let-7) [11]. Since then, 
the number of miRNAs has increased 
steadily. At the time of writing, the 
number of human mature miRNAs 
described in miRBase V20 is more than 
Figure 1. Abundance of regulatory ncRNA species versus protein coding genes in the human 
genome The numbers are based on Gencode V17 (http://www.gencodegenes.org/releases/17.
html).
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2,500 [12]. miRNAs are estimated to 
regulate the translation of up to 60% 
of protein-coding genes [13]. A single 
vertebrate miRNA has been described 
as targeting 200 messenger RNAs 
(mRNAs) on average, although some 
miRNAs regulate only a few targets 
[14]. Conversely, some protein-coding 
genes are regulated by only a single 
miRNA, while others are regulated by 
many miRNAs [15]. The importance 
of miRNAs as fine-regulators of gene 
expression has become clear since 
it was discovered that they play 
important roles in pivotal biological 
processes, such as development, cell 
proliferation, cell differentiation, and 
cell death [16–19]. 
miRNA biogenesis and 
mechanism of action
The process of miRNA biogenesis is 
quite characteristic for this subclass of 
ncRNAs. The primary miRNA transcript 
(pri-miRNA) is characterized by one or 
many hairpins that encompass the 
functional mature miRNA in their stem 
(Figure 2). Upon recognition by two 
nuclear enzymes, Drosha and DGCR8, 
the pri-miRNA is processed into one 
or several hairpins approximately 
70 nucleotide long; these are called 
precursor miRNAs (pre-miRNAs). 
They are exported into the cytoplasm 
by the nuclear export protein Exportin 
5 (XPO5) [20]. In the cytoplasm, the 
pre-miRNA can be recognized and 
are then processed by the RNase 
III enzyme Dicer, which removes 
the loop of the hairpin, resulting in 
a ~20 bp dsRNA molecule. One of 
the strands will be incorporated into 
the RNA-induced silencing complex 
(RISC) containing the Argonaute 
protein 2 (AGO2) and the GW182 
[21]. The RISC complex will target a 
mRNA transcript, based on sequence 
complimentarity between the miRNA 
sequence and nucleotides in the 3’-
UTR of the target [22]. It is thought 
that binding of the RISC complex to 
this target leads to deadenylation of 
the mRNA target, which will ultimately 
result in degradation if the homology 
between the entire miRNA sequence 
and the target is extensive [21,23]. 
Efficient targeting requires continuous 
base-pairing of the miRNA seed 
region (stretches of 6-8 nucleotides 
between positions 1-8 of the mature 
miRNA) with its target [10,23,24]. 
Computational target prediction 
approaches make use of this 
proposed rule to predict the targets 
of miRNA-induced silencing. These 
algorithms are based on searching 
for perfect Watson-Crick pairing 
between the miRNAs’ seed-sequence 
and the target mRNA sequence (most 
algorithms focus only on the 3’-UTR 
of genes) alone, or in combination 
with other rules, such as evolutionary 
conservation criteria to predict miRNA 
target sites [13,23]. Evolutionary 
conservation was important in 
defining the first identified miRNAs 
[25], but it is now becoming clear that 
many miRNAs are species-specific. 
In contrast, more than 60% of human 
protein-coding genes have been under 
selective pressure to maintain pairing 
to miRNAs [26]. miRNAs that appear 
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to have a common ancestor, and differ 
only in a few nucleotides, are grouped 
into the same miRNA family [27]. Until 
recently, it was assumed that miRNAs 
mainly target the 3’-UTRs of mRNAs 
[21], but it has now been shown that 
miRNA target sites can also be located 
in the 5’-UTRs of target mRNAs, or 
even in the coding region of these 
RNAs [21,28].
 Much attention has recently 
been paid to miRNA as potential 
biomarkers in circulation. Cell-free 
miRNAs have been described in 
multiple human body fluids, such 
as serum [29,30], saliva [31], 
cerebrospinal fluid (CSF) [32], and 
urine [33]. Most importantly, the 
disease-specific or even disease-
stage-specific nature of circulating 
miRNA profiles [34,35] implies that 
circulating miRNAs might potentially 
be used as novel biomarkers to 
evaluate health status or disease 
progression.
A role for miRNAs in disease
miRNAs have been shown to 
be involved in cancer and in 
neurodegenerative, cardiovascular 
and autoimmune diseases [15]. 
Changes in the amount of specific 
miRNAs will result in downregulation 
or upregulation of their targets, leading 
to deregulation of the pathways in 











Translation repression Target cleavage 
DGCR8 
Figure 2. miRNA biogenesis and mechanism of action. Stem loop sequences in primary microRNA 
(pri-miRNA) transcripts are recognized by DROSHA/DGCR8 and processed into 60–80-nucleotide 
long precursor microRNA (pre-miRNA) hairpins, which are subsequently translocated by exportin 
5. In the cytosol, the pre-miRNA is cleaved by Dicer to produce two single-stranded RNA strands, 
each of which can be loaded into the RISC complex, which is guided by the miRNA sequence to 
the 3’ UTR of the target mRNA. 
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deregulation of miRNA levels in human 
diseases can occur in different ways.
Firstly, altered functions of the 
enzymes involved in the miRNA 
biogenesis pathway can lead to altered 
miRNA profiles. Haploinsufficiency 
of DGCR8 accounts for over 90% 
of cases of DiGeorge syndrome. 
This dominantly inherited disorder is 
caused by the presence of hemizygous 
chromosome 22q11.2 deletions, 
which lead to various phenotypic 
defects including immunodeficiency 
and autoimmunity [36]. However, 
DGCR8 haploinsufficiency does not 
lead to an overall decrease in miRNA 
levels [37]. The presence of the XPO5 
inactive mutant traps miRNAs in the 
nucleus in a subset of human tumors 
[38]. Defects in Dicer have also been 
associated with disease, for example, 
recurrent somatic missense mutations 
in DICER1 have been identified in 
non-epithelial ovarian cancers [39]. 
In conclusion, defects in several 
members of the miRNA processing 
machinery have been reported. 
However, these changes never lead 
to dramatic overall changes of miRNA 
levels in the cell, which is consistent 
with the notion that miRNAs are 
essential for cell survival.
 Secondly, as pri-miRNA 
expression is regulated by RNA 
polymerase II and by the transcription 
factors that regulate the expression 
of protein-coding genes, the same 
epigenetic control mechanisms 
are involved in regulating miRNA 
expression. Transcriptional 
repression of miRNAs by promoter 
hypermethylation was found in many 
human tumors [40], for example, the 
miR-200 family is involved in the 
control of the epithelial-mesenchymal 
transition (EMT). In EMT, epithelial cells 
lose their adherence and polarity, and 
start to migrate. The miR-200 family 
downregulates ZEB1 (zinc finger 
E-box-binding homeobox 1) and ZEB2 
(zinc finger E-box-binding homeobox 
1), two important transcriptional 
repressors of genes involved in cell 
adherence (E-cadherin) and polarity 
(CRB3 (crumbs protein homolog 
3) and LGL2 (lethal giant larvae)). 
Thus hypermethylation of miR-200 
family members in cancer leads to 
upregulation of ZEB1 and ZEB2, 
leading to decreased adherence 
and polarity [41]. Similarly, histone 
modifications might also affect miRNA 
expression levels. For instance, SIRT1 
(sirtuin 1), a NAD-dependent histone 
deacetylase involved in control of 
axon growth and degeneration, was 
recently found to directly suppress the 
expression of miR-138 in response to 
peripheral nerve injury [42].
 Thirdly, different types of 
genetic alterations to miRNA genes 
or to their regulatory motifs can have 
deleterious consequences. In fact, the 
first example of the involvement of 
miRNAs in cancer was the description 
of a deletion of chromosome 13q14 in 
chronic lymphocytic leukemia patients. 
The deleted area contains the miR-
15a and miR-16-1 genes that target 
the anti-apoptotic/pro-survival gene 
BCL-2 (B-cell lymphoma 2) [43] and 
thus deletion of this region contributes 
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to the greater survival characteristics 
of cancerous cells. For the purpose of 
this review, we will focus on the most 
common type of genetic variants, 
SNPs, and show how they affect the 
function of miRNAs.
Genetic variation and miRNA 
function
There are many ways in which disease-
associated SNPS can affect miRNA 
levels. Firstly, mutations in miRNA 
biogenesis genes (Figure 2) can affect 
miRNA processing, which, in turn, can 
contribute to disease. For instance, 
the homozygous presence of SNP 
rs2073778, located in DGCR8, was 
found to be associated with a 4-fold 
increased risk of non-muscle bladder 
cancer progression [44]. Another 
example is the presence of SNP 
rs3742330 (A>G) in the Dicer gene, 
which is associated with increased 
survival of T cell lymphoma patients. 
Homozygous individuals carrying 
the GG genotype had a significantly 
increased overall survival [45].
 Secondly, SNPs in pri-miRNA 
and pre-miRNA can affect miRNA 
maturation efficiency (Figure 3A). For 
example, SNP rs11671784 in the 
miR-27a gene reduces gastric cancer 
risk by impairing the processing of 
pre-miR-27a to mature miR-27a. It 
was hypothesized that downregulated 



































Figure 3. Genetic variants and their influence on microRNAs (A) SNPs occurring in pri-miRNA 
sequences can affect miRNA processing. (B) SNPs changing the sequence of the mature miRNA 
can prevent binding to the original target and cause binding to alternative targets. (C) SNPs located 
within the 3’-UTR of the target can modulate miRNA-mRNA interaction in three ways: (1) a novel 
miRNA binding site is created, (2) a miRNA target site is disabled, and (3) the strength of binding 
can be attenuated, the mature miRNA sequence in blue indicates a weakness of binding and in red 
shows the strength of binding.
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increased expression level of its target 
gene HOXA10 (homeobox A10), and 
that changes in this gene have been 
associated with oncogenesis [46]. 
 Thirdly, SNPs affecting the 
promoters of miRNAs can affect 
expression of the miRNA in question. 
SNP rs57095329, which confers risk 
of systemic lupus erythematosus 
(SLE), is located in the miR-146a 
promoter (Figure 3B). Individuals 
carrying the risk allele in the promoter 
showed lower expression levels of 
miR-146a [47].
 Fourthly, SNPs can alter 
the binding efficiency of miRNAs to 
mRNA targets (Figure 3C) and SNPs 
in both miRNAs or in target mRNAs 
can affect miRNA-target interaction. 
An example of such an event is SNP 
rs3853839, which is associated with 
SLE susceptibility in Eastern Asians 
[48]. This SNP is located in the 3’ UTR 
of the TLR7 gene and potentially has a 
negative effect on the binding of miR-
3148. Risk allele carriers of this SNP 
display an increased TLR7 mRNA 
half-life, resulting in increased TLR7 
(Toll-like receptor 7) expression levels 
[49]. SNPs in miRNAs or target mRNAs 
can also confer the potential binding to 
different miRNA-target combinations 
(Figure 3C). A SNP in the 3’ UTR may 
create a sequence match to the seed 
of a miRNA that was not previously 
associated with the given mRNA [50]. 
Gong et al. predicted that 52% of 
SNPs in the dbSNP database (release 
132) would be able to create novel 
miRNA binding sites [51].
 The identification of GWAS 
SNPs in miRNA target sites helps with 
prioritizing functional variants. The 
first GWAS signal that was explained 
by polymorphic miRNA targeting was 
the synonymous SNP (c.313C>T) in 
the 3’ UTR of IRGM (immunity-related 
GTPase family M protein), a GTPase 
involved in regulating immunity. This 
SNP confers risk to Crohn’s disease 
by decreasing the binding of miR-
196 [52]. Another example is the 
presence of SNP rs1625579, which 
is associated with schizophrenia and 
located in the intron of a putative 
primary transcript for the mir137 gene. 
This SNP alters the seed sequence of 
miR-137, which is known to regulate 
neuronal development. Interestingly, 
four other genes associated with 
schizophrenia (TCF4 (transcription 
factor 4), CACNA1C (calcium channel, 
voltage-dependent, L type, alpha 1C 
subunit), CSMD1 (CUB and Sushi 
multiple domains 1) and C10orf26 
(chromosome 10 open reading frame 
26)) contain predicted target-binding 
sites for miR-137, suggesting that 
the expression levels of these four 
genes might be affected by multiple 
mechanisms [53]. As a last example, 
it was suggested that SNP rs13702, 
which is located in the 3’-UTR of 
lipoprotein lipase and potentially 
disrupts the binding site of miR-410, 
could modulate the effect of diet on 
plasma lipid levels [54]. 
 The strongest proof for the 
functionality of a SNP is an expression 
quantitative trait locus (eQTL) effect 
of the SNP on a transcript. In 2012 
Gamazon et al. showed that 25% of 
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European 3’-UTR SNPs and 18% of 
African 3’-UTR SNPs predicted to 
alter miRNA-binding sites did indeed 
have a cis-eQTL effect [55]. In another 
study using publically available eQTL 
datasets, 26 eQTL SNPs were 
predicted to create, disrupt, or change 
the target site of miRNAs in genes 
encoding xenobiotic metabolizing 
enzymes [56].
Bioinformatic and high-
throughput methods for 
studying miRNA function
Novel genomics techniques, such 
as next-generation sequencing, and 
analysis methods, such as eQTL 
analyses, yield a wealth of data 
and hypotheses. Concurrent with 
the increase in the amount of data, 
web-based applications and online 
databases have been developed 
that can be used to analyze miRNA 
data (Table 1). The main catalog of 
microRNA sequences is miRBase, 
which containing 1,872 human 
precursor miRNAs and 2,578 human 
mature miRNA sequences (miRBase 
V.20) [12]. Algorithms to predict 
miRNA-mRNA interaction, such 
as TargetScan [26], miRanda [57], 
TarBase [58] and PicTar [14], use 
miRBase to perform their miRNA-
target predictions.
 Several useful algorithms 
have now been developed to identify 
SNPs that potentially affect miRNA-
binding sites, such as Patrocles 
[59], PolymiRTs [60], miRSNP [61], 
microSNiPer [62], miRdSNP [63], 
and miRNASNP [51]. Most of these 
applications use the above target 
prediction algorithms for their 
predictions. MiRNASNP [51] goes 
a step further and also investigates 
whether SNPs affect pre-miRNAs 
and miRNA seed sequences. As 
mentioned above, the most powerful 
indication of a SNP’s functionality is 
to find an eQTL effect. In the study 
by Gamazon et al., described above, 
the authors examined SNPs from the 
HapMap Consortium [64] located in 
the 3’ UTRs of genes with cis-eQTL 
effects using TargetScan, miRBase, 
Pictar, TarBase, Patrocles and 
PolymiRTs. This detailed analysis 
identified 32 3’ UTR eQTL SNPs that 
potentially affect miRNA binding [55].
Since miRNAs may have many targets, 
high-throughput methodologies are 
needed to analyze the data. In the 
miRNA field, promising approaches 
involve cross-linking RNA (mRNA 
and miRNAs) to the RISC complex, 
immunoprecipitation of these 
complexes by capturing Argonaute 
proteins (most often antibodies 
against Argonaute are applied or cell 
lines are used that express tagged 
Argonaute proteins), and sequencing 
of the mRNA targets in the complex. 
Examples of such techniques are 
AGO2 HITS-CLIP [65], PAR-CLIP [66], 
and CLIP-seq [67]. The disadvantage 
of these assays is that they do not 
yield information on specific miRNAs 
binding to specific targets and, 
therefore, the miRNA of interest is 
often overexpressed to enrich for 
complexes with this specific miRNA.  
 However, in a recent paper by 
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Helwak et al. CLASH (cross-linking, 
ligation, and sequencing of hybrids) 
was described [68]. In this method, 
loaded RISC complexes are first 
cross-linked, isolated by Argonaute 
immunoprecipitation, and then the 
RNA in these complexes is ligated 
forming hybrid miRNA-target mRNA 
sequences that are sequenced. This 
provides a high-throughput method 
to identify the targets to which the 
miRNAs bind and gives an idea of 
which fraction of the RISC complexes 
in the cell is occupied by specific 
miRNAs.
Long non-coding RNAs
Long non-coding RNAs (lncRNAs) are 
a heterogeneous group defined as 
transcripts more than 200 nucleotide 
(nt) in length that exhibit no coding 
potential [69–71]. They can be 
isolated from nuclear as well as 
cytosolic fractions, may or may not be 
polyadenylated, and >95% of them 
display alternative splice isoforms 
[70,72]. In comparison with protein-
coding genes, lncRNAs have longer, 
but fewer, exons [70,73]. LncRNA 
promoter regions are similarly 
conserved between vertebrates as 
promoters of protein-coding genes. 
In contrast lncRNA exons are less 
well conserved between these 
species [69,74]. Like miRNAs, their 
expression is not regulated by RNA 
species-specific transcription factors 
or RNA polymerase molecules. It is 
becoming clear that lncRNAs exhibit 
cell-type-specific expression profiles 
[69] and that in their specific cellular 
background they can be expressed at 
levels, similar to the levels of protein-
coding RNAs. The origin of lncRNAs is 
still under debate, but a recent study 
[75] has reported that more than two-
thirds of mature lncRNA transcripts 
contain transposable elements 
(TEs), whereas only 4% of protein-
coding genes contain these ‘jumping 
genes’ [76]. This observation led to 
the postulation that the majority of 
lncRNAs have arisen via insertion of 
TEs. For example, the rodent-specific 
brain cytoplasmic RNA 1 (BC1), the 
anthropoid primate-specific brain 
cytoplasmic RNA 200-nucleotide 
(BC200), and the strepsirhini primate-
specific G22 lncRNAs, form a 
family of lncRNAs which originate 
independently from insertion of TEs, 
resulting in lncRNAs that locate to 
dendrites in different mammalian 
species [77–80]. 
 The first lncRNAs (H19 and 
Xist (X-inactive specific transcript)) 
were discovered using traditional 
gene mapping approaches in the 
early 1990s [81–83] and were 
considered to be rare exceptions to 
the then central dogma of molecular 
biology. Using tiling arrays HOTAIR 
(HOX antisense intergenic RNA) and 
HOTTIP (HOXA transcript at the distal 
tip) were discovered in the homeobox 
gene regions (HOX clusters) [84,85]. 
In 2009, Guttman et al. was the first 
to describe a genome-wide approach 
for discovering lncRNAs that yielded 
1,600 novel mouse lncRNAs. In this 
study gene expression data and the 
presence of chromatin marks for 
122
promoter regions and gene bodies 
was integrated with the known 
annotations of coding transcripts to 
identify lncRNAs [74]. Since then, 
thousands of lncRNAs have been 
identified using similar approaches 
in the mouse and human genomes 
[69,86]. When used in combination 
with next-generation RNA sequencing, 
additional information can be obtained 
about lncRNA exon-intron structure 
as well as about the abundance of 
these transcripts [87–93]. Cabili et 
al. combined chromatin marks and 
RNA-sequencing (RNA-seq) data to 
generate the human lincRNA catalog, 
containing more than 8,000 lincRNAs 
determined across 24 different human 
cell types and tissues [73]. Although 
more than 13,500 human lncRNAs 
have been annotated by ENCODE, 
only a few dozen have been studied 
in more detail so far. The challenge is 
now to elucidate the function of these 
lincRNAs. 
Classes of lncRNAs and 
mechanism of action
Classification of lncRNAs based 
on genomic location
The size limit of >200 nucleotides 
used to define lncRNAs is an arbitrary 
cut-off based on RNA isolation 
protocols and their size exclusion limit 
in the past, which potentially leads 
to the capture of a heterogeneous 
group of different transcripts with 
respect to function. Although different 
nomenclatures are used, in this review 
we will adhere to the classification 
based on the lncRNAs location relative 
to the nearest known protein-coding 
gene as described in GENCODE 
[70]. This subclassification leads to 
four broad categories (Figure 4). The 
long intergenic non-coding RNAs 
(lincRNAs) are the largest group of 
lncRNAs, accounting for approximately 
5,000 human genes according to 
the GENCODE dataset V17 [70] 
or approximately 8,000 according 
to the human lincRNA catalog [73]. 
LincRNA genes do not overlap or lie 
next to protein-coding genes [74,94]. 
The second most prevalent class of 
lncRNAs is the antisense lncRNAs 
that is transcribed from the strand 
opposite of the protein-coding genes, 
which they are overlapping. Based on 
their complete or incomplete overlap, 
antisense lncRNAs can be subdivided 
into various subclasses, for example, 
intronic antisense lncRNAs when the 
lncRNA transcript falls completely 
within the boundaries of an opposing 
coding intron, or natural antisense 
transcripts (NATs) with partial 
overlap, mainly around the promoter 
or terminator site of the coding gene 
[95,96]. For antisense transcripts it 
holds true that the sense-antisense 
pairs are often co-expressed together, 
that they share a similar pattern of 
evolutionary conservation [97], and 
that the antisense transcript modulates 
the expression of the sense transcript 
by the formation of a sense-antisense 
RNA duplex [96]. The third subclass 
of lncRNAs comprises the sense 
lncRNA transcripts. Such transcripts 
are located on the same strand and 
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transcribed in the same direction as a 
protein-coding gene. This organization 
is much less prevalent. In total, fewer 
than 1,000 sense lncRNAs have been 
identified, overlapping completely or 
partially with protein-coding genes. 
To date, this subclass is poorly 
characterized compared with the 
other lncRNAs. The fourth subclass 
of lncRNAs is the bi-directional or 
divergent group. These transcripts 
are located on the antisense strand 
(opposite of the protein-coding gene); 
they have their transcription start site 
(TSS) close to the TSS of the protein-
coding gene, but are transcribed in 
the opposite direction. The majority 
of these bi-directional pairs are co-
expressed together and conserved 
between human and mouse [98,99].
Classification of lncRNAs 
based on molecular mechanism 
(lncRNA archetypes)
LncRNAs can interact with DNA or 
RNA as well as proteins. Although the 
detailed mechanism of action is still 
unknown for most of the annotated 
lncRNAs, the few examples available 
show the complexity of lncRNA 
biology. LncRNAs control multiple 
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Figure 4. Classification of lncRNAs based on position relative to the nearest protein-coding gene 
(A) Long intergenic non-coding RNA (lincRNA) genes do not overlap or neighbour protein-coding 
genes. (B) Antisense lncRNAs are transcribed from the strand opposite of the protein-coding gene 
with whom they are overlapping. Antisense lncRNAs can be subdivided into (1) intronic antisense 
lncRNAs, when the transcript falls completely within the boundaries of an opposing coding intron; 
or (2) natural antisense transcripts (NATs) which partially overlap the coding gene. (C) Sense 
lncRNAs are located on the same strand and transcribed in the same direction as a neighbouring 
protein-coding gene. (D) Bidirectional or divergent lncRNAs are located on the antisense strand 
(opposite of the protein-coding gene) and their transcription start site (TSS) is close to the TSS of 
the protein-coding gene. These lncRNAs are transcribed in the opposite direction relative to the 
protein-coding gene. Color legend: protein coding genes (blue) and lncRNA genes (red).
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gene expression process. They have 
been implicated in post-transcriptional 
gene regulation by controlling 
processes, like protein synthesis, 
RNA maturation, and RNA transport, 
and have been shown to control 
transcriptional gene silencing via 
epigenetic regulation and chromatin 
remodeling [90,100–104].
In 2011, Wang and Chang [101] 
proposed dividing lncRNAs into four 
archetypes based on their molecular 
mechanisms, in an attempt to simplify 
the complexity of action (Figure 5). The 
mechanism 1, the signaling archetype, 
is carried out by lncRNAs that act as 
molecular signals and may activate or 
silence other genes without the need 
for translation (Figure 5A). This mode 
of action is important for fast, targeted 
regulation, for example, carried out 
by lncRNAs involved in embryonic 
development (HOTAIR and HOTTIP, 
both regulating homeobox genes) 
[84,85,105], in the DNA damage 
response (e.g. lincRNA-p21 and 
PANDA (p21-associated ncRNA DNA 
damage activated lncRNA) [106,107], 
in stress responses (e.g. COLDAIR 














Figure 5. Four archetypes of lncRNA mechanism of action (adapted from Wang and Chang, 2011)
(A) Signaling archetype: some lncRNAs act as molecular signals activating (1) or silencing (2) 
other genes without own translation. (B) Decoy archetype: some lncRNAs compete with another 
sequence/structure (such as miRNAs, transcription factors, or RNA-binding proteins) for binding. 
(C) Guide archetype: lncRNAs that bind specific proteins and transport them closer to specific 
target sequence. This interaction might be (1) direct - when the lncRNA-protein heteroduplex 
(ribonucleoprotein complex) binds directly to DNA, or (2) indirect - when the interaction between 
lncRNA-protein is mediated via another protein located on the DNA. (D) Scaffold archetype: 
lncRNAs that bind multiple proteins, bringing them in close proximity to facilitate interactions and, 
for example, allow the formation of ribonucleoprotein complexes.
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RNA), COOLAIR (cold-induced long 
antisense intragenic RNA)) [108,109], 
and in somatic cell reprograming 
(e.g. lincRNA-ROR (regulator of 
reprograming)) [110,111]. 
 The second mechanism of 
action is the decoy mechanism (Figure 
5B). LncRNAs exploiting this strategy 
(e.g. Gas5 (growth arrest-specific 
transcript 5), MALAT1 (metastasis-
associated lung adenocarcinoma 
transcript 1), TERRA (telomeric 
repeat-containing RNA) and PANDA) 
can act as a decoy that binds to and 
intervene with the function of other 
RNAs or proteins, such as miRNAs, 
transcription factors, or RNA-binding 
proteins. These lncRNAs, known 
as “sponges”, can compete with 
another sequences or structures 
for binding and are considered as 
negative regulators. GAS5 acts as 
a decoy glucocorticoid-response 
element (GRE) and competes 
with DNA GREs for binding to the 
glucocorticoid receptor [112]. PANDA 
binds to the transcription factor NF-
YA and prevents the activation of 
NF-YA-induced pro-apoptotic targets 
[107,113]. 
 The third lncRNA mechanism 
is the ability to act as a guide archetype, 
for example, by binding proteins and 
transporting the created complex 
to specific targets, for example, 
chromatin modification enzymes to 
DNA, where the interaction may be 
directly between this complex and the 
DNA, or indirectly with heteroduplex 
protein-DNA (Figure 5-3). These 
lncRNAs may interact as activators 
or repressors with neighboring (cis) 
or distant (trans) genes. Examples of 
lncRNAs employing this mechanism 
are HOTAIR, lincRNA-p21, Xist, 
COLDAIR and Jpx (just proximal 
to XIST). COLDAIR of Arabidopsis 
thaliana binds to Polycomb repressive 
complex 2 (PRC2) and transfers it to 
chromatin of the flowering locus C 
repressor, which induces repression 
of this locus through trimethylation 
of histone H3 lysine 27 (H3K27), to 
inhibit flowering during unfavorably 
low temperatures [108].
 The fourth mechanism is 
acting as a scaffold (Figure 5D), for 
instance by bringing bound proteins 
into a complex or in spatial proximity. 
Examples of lncRNAs exploiting this 
strategy are ANRIL (antisense ncRNA 
in the INK4 locus), which functions as a 
scaffold for the chromatin remodeling 
complex PRC1 (polycomb repressive 
complex 1) [114], HOTAIR (scaffold 
for PRC2 binding it to the LSD1 (lysine-
specific demethylase 1A) complex) 
[84,105,115], and TERC (telomerase 
RNA component) that scaffolds the 
telomerase complex [116]. From the 
above examples, it follows that several 
lncRNAs can exercise more than one 
archetypal action, thereby adding to 
the complexity of the lncRNA world.
LncRNAs in human disease
The lncRNAs that have been studied in 
most detail have emerged as important 
regulators of gene expression. In many 
diseases the expression of protein-
coding genes is deregulated and 
evidence is now accumulating that 
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altered lncRNA function might be one 
of the causes involved. Below we will 
describe examples of lncRNAs known 
or suggested to be involved in the 
etiopathology of different disorders. 
 Most evidence for a role 
of lncRNAs in disease has been 
found in cancer. Many lncRNAs have 
been described that exhibit altered 
expression levels in cancer cells 
compared to healthy tissue of the 
same origin [117]. LncRNA MALAT1, 
also known as NEAT2 (nuclear-
enriched abundant transcript 2), was 
initially discovered as a predictive 
biomarker for metastasis development 
in lung cancer [118,119], but only 
almost ten years later, its mechanism 
of action was clarified. MALAT1 
acts by inducing the expression of 
metastasis-associated genes [120] 
and it was recently reported that the 
in vitro metastasis of human lung 
cancer (EBC-1) cells can be inhibited 
by inhibiting MALAT1 using antisense 
oligonucleotides [120,121]. It is 
disappointing that three independently 
derived Malat1 knockout (Malat1-
KO) mouse models exhibit no 
obvious phenotype or histological 
abnormalities [54–56]. 
 Another lncRNA involved 
in metastasis is HOTAIR, which 
interacts with PRC2 and alters 
chromatin to a metastasis-promoting 
state [122]. In approximately one-
quarter of human breast cancers, 
HOTAIR is highly induced, while its 
elevated levels are also predictive of 
metastasis and disease progression 
in other cancers, such as colon, 
colorectal, gastro intestinal, pancreatic 
and liver cancer [115,123–126]. 
LncRNAs are also connected to other 
processes involved in human cancer 
development and progression. ANRIL, 
GAS5 and lincRNA-p21 are involved 
in the escape of growth suppression 
by regulating tumor suppressor genes 
(ANRIL) or apoptosis regulators (GAS5, 
lincRNA-p21). TERRA and TERC 
(telomerase RNA component) regulate 
replicative immortality [127,128]. 
MALAT1 and HOTAIR activate cancer 
invasion and metastasis by regulating 
cell motility-related genes (MALAT1) 
or retargeting of PCR2 complex and 
changing it to a pattern similar to the 
one of embryonic fibroblasts, causing 
increase in cancer cell invasiveness 
and their ability to metastase (HOTAIR) 
[115,120,129]. The lncRNAs ‐HIF 
(antisense to hypoxia inducible factor 
‐ (HIF‐)) and tie-1AS (tyrosine kinase 
containing immunoglobulin and 
epidermal growth factor homology 
domain-1 antisense) induce 
angiogenesis [94,130]. PCGEM1 
(prostate-specific transcript 1), UCA1 
(urothelial cancer associated 1, also 
known as CUDR, cancer upregulated 
drug resistant), SPRY4-IT1 (SPRY4 
intronic transcript 1), and PANDA are 
involved in suppressing apoptosis 
[107,131–133]. Some lncRNAs have, 
as yet, only been associated with one 
specific type of cancer. PCGEM1, 
PCA3 (prostate cancer antigen 3, 
known also as DD3, differential display 
code 3) and PCNCR1 (prostate 
cancer ncRNA 1) are involved in 
prostate cancer, while HULC (highly 
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up-regulated in liver cancer) is 
involved with liver cancer [131,134–
138]. In contrast, other lincRNAs (e.g. 
HOTAIR and MALAT1) appear to be 
broadly deregulated in carcinogenesis 
[118,124,125,139,140].
 More recently, data has been 
generated that shows that lncRNAs 
also have roles in other diseases. 
Some human pathological phenotypes 
are caused by epigenetic changes 
and imprinted lncRNA gene clusters 
have been associated with these 
diseases [141]. Examples of these are 
the imprinting-related, neurogenetic 
Angelman syndrome and Beckwith-
Wiedemann syndrome (BWS) [142]. 
Angelman syndrome is caused by a 
loss-of-function of ubiquitin-protein 
ligase E3A (UBE3A), also known as 
E6AP [143]. Although in the majority 
of human tissues, both copies of 
the UBE3A gene are expressed, 
in neurons one copy is silenced by 
UBE3A-AS1 (ubiquitin-protein ligase 
E3A antisense RNA 1) [144]. In patients 
suffering from Angelman syndrome, 
the other (active) allele has either been 
deleted or inactivated [144]. In more 
than half of the cases of Beckwith-
Wiedemann syndrome, maternal 
methylation at DMR2 (differentially 
methylated imprinting center 2) has 
been lost [145]. This center contains 
the two protein-coding genes 
CDKN1C (cyclin-dependent kinase 
inhibitor 1C) and KCNQ1 (potassium 
voltage-gated channel member 1) 
and antisense lncRNA KCNQ1OT1 
(KCNQ1 overlapping transcript 
1) [146]. In healthy individuals the 
maternal KCNQ1OT1 lncRNA is 
silenced via methylated KCNQ1 and 
CDKN1C is transcribed to its protein 
p57, a negative regulator of cell 
proliferation [146]. In 60% of patients 
with BWS, the KCNQ1 gene is not 
methylated, KCNQ1OT1 lncRNA is 
transcribed from both alleles, leading 
to cis repression of CDKN1C and 
disease [145–147].
 LncRNAs have also been 
associated with other neurological 
disorders, such as BACE1-AS or 
BC200 in Alzheimer disease, HAR1 
(human accelerated region 1 lncRNA) 
in Huntington disease, and ATXN8OS 
(Ataxin 8 opposite strand lncRNA) 
in spinocerebellar ataxia type 8 
[142,148,149]. In Alzheimer disease, 
the protein-coding gene BACE-1 (‐-site 
amyloid precursor protein-cleaving 
enzyme) cleaves amyloid precursor 
protein (APP) to ‐-amyloid peptide (A‐), 
the accumulation of which (amyloid 
plaques) is associated with disease. 
LncRNA BACE1-AS, located on the 
antisense strand to BACE1, binds 
complementarily to BACE1 mRNA, 
increases its stability, regulates 
BACE1 translation, and thereby the 
production of A‐ [150]. BACE1-AS also 
prevents miRNA-induced repression 
of BACE-1 by masking the binding 
site for miR-485-5p, by competing for 
the same region on exon 6 of BACE-
1 [151]. Two- to three-fold increased 
levels of BACE1-AS and a smaller 
increase (1.5x) of BACE-1 have been 
documented post mortem in the brains 
of patients with Alzheimer disease 
[150].
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 Besides their actions in 
cancer and neurological diseases, 
lncRNAs also exhibit aberrant 
expression in other disease states, 
such as facioscapulohumeral 
muscular dystrophy (FSHD). FSHD 
is a common, progressive, genetic 
disease of skeletal muscle caused 
by deletions that reduce the number 
of D4Z4 repeats in the FSHD locus 
at chromosome 4q35 [142,152]. 
Under physiological conditions, D4Z4 
repeats recruit Polycomb complexes 
resulting in chromatin reorganization 
and causing repression of 4q35 genes 
[153]. In contrast, in FSHD patients, a 
deletion of D4Z4 repeats results in 
cis production of the DBE-T lncRNA 
that binds to protein complexes, 
reorganizes the chromatin state of 
the FSHD locus, and reactivates the 
repressed 4q35 genes [153].
Genetic variants and lncRNA 
function
As yet, how far lncRNAs are affected 
by genetic alterations related to the 
disease phenotype is unknown. The 
larger alterations, like chromosomal 
rearrangements (translocations, 
amplifications, or deletions) do affect 
the expression of lncRNAs that are 
involved in disease phenotypes. For 
example, two different balanced 
translocations (t(8;12)(q13;p11.2) 
and t(4;12)(q13.2-13.3;p11.2)) 
affecting chromosome 12p have 
been associated with the human 
brachydactyly type E phenotype 
[154,155]. The lncRNA DA125942 in 
the affected 12p region was recently 
described as interacting in cis with 
Parathyroid hormone-like hormone 
(PTHLH, which is a regulator of 
endochondral bone development) and 
in trans with SOX9 (Sex determining 
region Y-box 9, which acts during 
chondrocyte differentiation) [111,154]. 
Another balanced translocation 
(t(1;11)(q42.1;q14.3)) has been 
associated with schizophrenia and 
other psychiatric disorders [156,157]. 
This particular translocation affects 
two genes, the protein-coding 
disrupted in schizophrenia 1 gene 
(DISC1) and the antisense lncRNA 
disrupted in the schizophrenia 2 gene 
(DISC2) [157,158]. The same DISC1/
DISC2 region was also associated 
with a 1q42 deletion in an autism 
spectrum disorder [159].
 The interactions of lncRNAs 
with other molecules are probably 
governed by lncRNA structure, rather 
than by sequence. As it is difficult 
to predict the structure of larger 
RNA molecules, it is a challenge to 
understand how small mutations 
(small insertions/deletions or SNPs) 
are involved in disease etiopathology. 
Here we describe a few scenarios 
that can be envisioned. Firstly, SNPs 
may affect the expression level of 
lncRNAs. SNPs can be located in 
promoter sequence and directly 
alter the expression of lncRNAs 
(Figure 6A) or change the binding 
of inhibitory complexes, thereby 
allowing expressing of lncRNAs that 
are not expressed under physiological 
circumstances (Figure 6B). Secondly, 
SNPs within lncRNA genes may cause 
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alternative splicing of the transcript 
(Figure 6C) or affect its secondary 
structure (Figure 6D). This can lead 
to an altered function of the lncRNAs. 
For instance, the chromosomal region 
9p21 (previously described as a 
“gene desert”) harbors the ANRIL 
lncRNA (also known as CDKN2BAS 
or CDKN2B-AS1). Many SNPs 
located within or around this lncRNA 
have been associated in GWAS with 
a susceptibility to atherosclerotic 
vascular disease, coronary artery 
disease, stroke, myocardial infarction, 
aortic aneurysm, type 2 diabetes, and 
several types of cancers [160,161]. 
Exactly how these SNPs contribute to 
disease is not yet known. It is unclear 
whether they directly regulate the 
expression level of ANRIL or whether 
they disturb the binding site of 
transcription factor STAT1 (ANRIL’s 
repressor) in ANRIL’s enhancer (Figure 
6B) [162]. SNPs may also modulate 
ANRIL transcripts by inducing exon 
skipping, resulting in shorter splice 
variants with reduced efficiency or 
non-functional isoforms (Figure 6C) 
[160].
Bioinformatics tools and high-
throughput applications for 
studying lncRNAs
As lncRNAs are a relatively novel 
class of transcripts, there are not yet 
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Figure 6. Functional consequences of mutations on lncRNAs and their function  Mutations located 
in regions involved in transcriptional control (e.g. promoters, enhancers, 3’-UTR) might result in: 
(A) direct alteration of the amount of lncRNA transcripts; or (B) indirect alteration of lncRNA levels 
when enhancer or repressor sites are affected. Mutations located in exons of lncRNAs might result 
in alternative splicing leading to loss-of-function (C). Mutations might also alter lncRNA function by 
affecting their secondary structure (D).
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study of lncRNA function. To date, a 
couple of lncRNAs databases and 
catalogs are available (Table 1), such 
as Lincipedia [163], LncRNAdb [79], 
and the Human lincRNA catalog [73]. 
LncRNAdb contains a comprehensive 
collection of eukaryotic lncRNAs and 
relevant information, such as RNA 
sequence, structure, genomic location, 
expression profiles, subcellular 
localization, conservation and function 
[79]. The Human lincRNA catalog [73] 
focuses only on human lincRNAs and 
contains more than 8,000 lincRNAs 
defined by more than 30 properties. 
Expression data across 24 tissues 
and cell types is available in this 
database. Data from both databases 
can be visualized and analyzed using 
the University of California Santa Cruz 
(UCSC) genome browser [164]. In 
the same browser, it is also possible 
to annotate ncRNAs with the latest 
updated genome-wide data from 
large international consortia, such as 
ENCODE and Functional Annotation 
of the Mammalian Genome (FANTOM) 
[165–167].
 Co-expression analysis is 
a promising strategy to predict the 
mechanism of action of lncRNAs 
of interest. This type of analysis 
predicts functions for molecules 
of unknown gene products, based 
on co-expression data and taking 
into account the known functions or 
mechanisms of the co-expressed 
genes (“guilt by association”). Two 
examples of such tools are Gene 
Network (www.genenetwork.nl/
genenetwork (Karjalainen and Franke 
et al., manuscript in preparation) or 
Gemma (http://www.chibi.ubc.ca/
Gemma/home.html)[168]. However, 
the data most commonly used for 
these analyses comes from arrays. 
Although nearly all the arrays were 
designed to study the expression of 
protein-coding genes, several of them 
also carry probes for lncRNAs. Kumar 
et al. (2012) took advantage of this and 
used microarray data to investigate 
the association of SNPs with the 
expression levels of lincRNAs by 
using eQTL and a platform containing 
approximately 2,000 lncRNA probes 
[9]. They discovered 112 cis-
regulated lincRNAs, of which 45% 
were replicated in an independent 
dataset. A remarkable 75% of these 
SNPs affected the expression of 
the lincRNA but did not affect the 
expression of neighboring protein-
coding genes. Expression microarray 
platforms probing both protein-coding 
transcripts and non-coding RNAs 
will enable co-expression analyses 
of these RNA classes. The data 
can then be used to link lncRNAs to 
pathways, using existing data for the 
coding genes with which they are co-
expressed.
 In the near future, enough 
transcriptomic data is expected to 
be generated by next- generation 
sequencing to allow in depth co-
expression analysis. The initial studies 
in the field were mostly focused 
on lncRNAs in the polyadenylated 
(polyA+) RNA fraction. More recently, 
a significant proportion of lncRNAs 
also present in the non polyadenylated 
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(polyA-) RNA fraction have been 
described [169]. For this reason, the 
latest focus is on both RNA fractions 
(polyA+, polyA-) as well as on different 
subcellular compartments (nuclear, 
cytoplasmic) [69,72]. It is expected 
that many more lncRNA transcripts 
will be identified [170].
 Because lncRNA function is 
based on RNA structure rather than on 
RNA sequence, it is difficult to predict 
lncRNA targets or to pinpoint the 
functional domains in these molecules. 
However, a new tool has recently been 
described that can be used to predict 
regions within chromatin-associated 
non-coding RNAs that can inserts 
themselves into DNA stretches, which 
are then likely to be able to form a 
triple helix structure [171].
 The techniques used for 
the genome-wide identification of 
lncRNA targets and binding partners 
employ methods similar to the ones 
described above for finding miRNA 
targets. Chromatin Isolation by RNA 
Purification (ChIRP) [172] and Capture 
Hybridization Analysis of RNA Targets 
(CHART) [173] are based on cross-
linking RNA in complex with DNA 
and/or protein, followed by capture 
techniques targeting the lncRNA in the 
complex. Subsequently, the protein 
component or DNA sequences in the 
complexes can be identified by mass 
spectrophotometry [172] or next-
generation sequencing, respectively. 
Conversely, since lncRNAs have been 
reported to be involved in targeting 
chromatin-modifying complexes 
to specific DNA sequences, one 
can cross-link complexes and 
immunoprecipitate these (e.g. the 
PRC2 complex), and then analyze the 
RNA component by sequencing (RNA 
immunoprecipitation-sequencing 
(RIP-SEQ) [174]. Finally, lncRNAs can 
be synthesized in vitro and hybridized 
with protein microarrays to identify 
lncRNA-protein interactions [99].
Perspectives
The rapid evolution of next-generation 
sequencing technologies and the 
expected drop in cost of assays 
means we will soon be able to 
sequence large numbers of genomes 
and transcriptomes. This will ultimately 
provide us with a nearly complete 
overview of disease-associated 
genetic variation. Transcriptome 
analysis will discover tens of thousands 
of new transcripts, many of which will 
be of a non-coding nature [170]. Most 
of the genetic variation associated 
with complex diseases is located 
within genomic regions that control 
transcription, rather than in protein-
coding areas. As the ncRNAs are now 
emerging as important regulators of 
expression, it is becoming clear that 
deregulation of gene expression might 
be the lynch-pin in many disease 
mechanisms. Because of the above it 
is essential to understand the function 
of ncRNAs in health and disease.
 What is already emerging 
and will complicate the study of the 
regulatory involvement of ncRNAs 
in human diseases even more, is 
that different classes of ncRNAs 
might interact. A few lncRNAs have 
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been reported to be precursors for 
different types of small ncRNAs, such 
as miRNAs or small nucleolar RNAs 
[69,175]. In addition, miRNAs and 
lncRNAs can regulate each other’s 
expression. For example, Zhang et al. 
(2013) reported miR-21 which is able 
to negatively regulate the expression 
of the GAS5 lncRNA. On the other 
hand GAS5 was able to repress miR-
21 [176]. LncRNAs can also act as 
microRNA ‘sponges’. The most striking 
is example is the circular lncRNA 
CDR1 (cerebellar degeneration-
related protein 1), which has been 
shown to contain approximately 70 
binding sites for miR-7. By binding 
miR-7 molecules CDR1 prevents 
binding of this miRNA to other miR-7 
targets [177,178].
 The availability of genomic 
and transcriptomic data will also lead 
to an increase in the number of ncRNA 
eQTLs associated with disease [9]. 
Once the causal mutations have 
been connected to specific ncRNAs, 
the next step will be to identify the 
targets/interaction partners of these 
transcripts, which is essential to fully 
understanding the mechanism of 
disease. Because both miRNAs and 
lncRNAs may act on many targets, 
high-throughput methods will need to 
be designed and applied. Eventually, 
genome-editing techniques might 
be applied to pinpoint the effects of 
a single SNP or of small deletions/
insertions by allowing alterations of 
wild-type alleles into risk alleles in 
eukaryotic cells [179].
 The ‘omics’-revolution started 
with the description of the sequence of 
the human genome. Since then state-
of-the-art high-throughput techniques 
and bioinformatic approaches have 
been developed, that were used to 
identify mutations that are associated 
with human diseases. It has now 
become apparent that a significant 
part of these mutations affect the 
expression or function of ncRNAs. 
To fully understand the function of 
these ncRNAs and how this function 
is affected in disease, biologists will 
need to investigate the function of 
individual ncRNAs. Because both 
miRNAs and lncRNAs exhibit cell 
type, and even cell developmental 
stage specific expression profiles, 
it is pivotal that this research will be 
performed in the relevant (disease 
associated) cell types.
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